Heart valve patients may ditch blood thinners for simple aspirin
NCT ID NCT07431762
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study compares aspirin to the blood thinner warfarin in 1058 people who just had a bioprosthetic heart valve replacement. For 6 months after surgery, participants take either daily aspirin or warfarin. The goal is to see if aspirin is just as safe and effective at preventing blood clots, strokes, and other complications, potentially offering a simpler treatment option.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
aspirin or warfarin
What this could lead to
If aspirin works as well as warfarin, patients could avoid the frequent blood tests and dietary restrictions needed with warfarin.
What could go wrong
This is a phase 4 trial, so the drugs are already approved, but it's still possible that aspirin is less effective at preventing clots, which could increase stroke risk.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for VALVE REPLACEMENT SURGERY are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Asan Medical Center
Seoul, 05505, South Korea
Contact
-
National Cerebral and Cardiovascular Center Hospital
Osaka, 564-8565, Japan
Contact
-
Osaka University Hospital
Osaka, 565-0871, Japan
Contact